Cardio-oncology Related to Heart Failure: Epidermal Growth Factor Receptor Target-Based Therapy

Heart Fail Clin. 2017 Apr;13(2):297-309. doi: 10.1016/j.hfc.2016.12.002.

Abstract

Cancer therapy targeting the epidermal growth factor receptor (EGFR)/erythroblastic leukemia viral oncogene B (ErbB)/human EGFR receptor (HER) family of tyrosine kinases has been successfully used in treatment of several malignancies. The ErbB pathways play a role in the maintenance of cardiac homeostasis. This article summarizes current knowledge about EGFR/ErbB/HER receptor-targeted cancer therapeutics focusing on their cardiotoxicity profiles, molecular mechanisms, and implications in clinical cardio-oncology. The article discusses challenges in predicting, monitoring, and treating cardiac dysfunction and heart failure associated with ErbB-targeted cancer therapeutics and highlights opportunities for researchers and clinical investigators.

Keywords: Cancer; Cardiac therapies; Cardiovascular toxicity; EGFR signaling; HER2 pathways; Heart failure; Targeted cancer therapeutics.

Publication types

  • Review

MeSH terms

  • ErbB Receptors / antagonists & inhibitors
  • Heart Failure / chemically induced*
  • Heart Failure / metabolism
  • Heart Failure / physiopathology
  • Heart Ventricles / physiopathology
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism
  • Neoplasms / physiopathology
  • Protein Kinase Inhibitors / adverse effects*
  • Protein Kinase Inhibitors / pharmacology
  • Signal Transduction / drug effects
  • Ventricular Function, Left / drug effects

Substances

  • Protein Kinase Inhibitors
  • EGFR protein, human
  • ErbB Receptors